TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7861022

Group type: EXPERIMENTAL
Intervention: Zidovudine monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine with >200 CD4 cells/mm3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zalcitabine added to zidovudine in zidovudine-experienced patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching to didanosine in zidovudine-experienced patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine administered to women after the first trimester
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy in zidovudine-experienced patients with <50 CD4 cells/mm3
Number of subjects: 0
Study: 1873448

Group type: COMPARATOR
Intervention: Vitamin A, 25,000 IU; beta-carotene, 50 mg; vitamin E, 800 IU; selenium, 400 micrograms (administered daily)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebos (administered daily)
Number of subjects: 350
Study: 6874485

Group type: EXPERIMENTAL
Intervention: Training group (20 inhalations to total lung capacity, held for 10 s each day for 6 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (nontraining)
Number of subjects: 16
Study: 31915235

Group type: EXPERIMENTAL
Intervention: VA-dual therapy (vonoprazan 20 mg + amoxicillin 750 mg twice/day)
Number of subjects: 335

Group type: COMPARATOR
Intervention: VAC-triple therapy (vonoprazan 20 mg + amoxicillin 750 mg + clarithromycin 200 mg twice/day)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: VA-dual therapy
Number of subjects: 335

Group type: COMPARATOR
Intervention: VAC-triple therapy
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 335
Study: 31034597

Group type: EXPERIMENTAL
Intervention: Oncologists' predictions
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Patients' predictions
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Caregivers' predictions
Number of subjects: 263
Study: 28937899

Group type: EXPERIMENTAL
Intervention: Ozone gas
Number of subjects: 80

Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2) base material
Number of subjects: 80
Study: 26800893

Group type: EXPERIMENTAL
Intervention: Cheongsangbangpoong-tang (CBT)
Number of subjects: 56
Study: 24390150

Group type: EXPERIMENTAL
Intervention: Adjuvant! Online
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Dutch breast cancer guideline 2012
Number of subjects: 303
Study: 23031366

Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa 20mg/kg biweekly for 26 weeks
Number of subjects: 0
Study: 19261038

Group type: EXPERIMENTAL
Intervention: Image integration-guided ablation (CartoMerge TM)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Conventional radiofrequency catheter ablation
Number of subjects: 290
Study: 17453967

Group type: EXPERIMENTAL
Intervention: 4 days of G-CSF administration
Number of subjects: 24

Group type: COMPARATOR
Intervention: 6 days of G-CSF administration
Number of subjects: 24
Study: 18084873

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg/day
Number of subjects: 105

Group type: COMPARATOR
Intervention: Paroxetine 20 mg/day
Number of subjects: 105
Study: 11680522

Group type: EXPERIMENTAL
Intervention: VAX-D
Number of subjects: 0

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 0
Study: 9838263

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8081180

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (all doses)
Number of subjects: 20
Study: 2692145

Group type: EXPERIMENTAL
Intervention: Prolonged antithrombotic treatment with anticoagulants or antiplatelet drugs (50 mg aspirin + 400 mg dipyridamole daily)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Placebo treatment after 3 months of active therapy
Number of subjects: 649
Study: 1096538

Group type: EXPERIMENTAL
Intervention: Piracetam 4.8 g/day for 3 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no piracetam)
Number of subjects: 18
Study: 31818787

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg/day
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Vortioxetine 5 mg/day
Number of subjects: 1811

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1811
Study: 29482372

Group type: EXPERIMENTAL
Intervention: Brochures with a short personal narrative
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Brochures without a personal narrative
Number of subjects: 1135

Group type: COMPARATOR
Intervention: No-exposure control arm
Number of subjects: 1135
Study: 28770409

Group type: EXPERIMENTAL
Intervention: Trigger Point (TP) therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trigger Point (TP) therapy combined with Lymphatic Drainage (LD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 0
Study: 25998450

Group type: EXPERIMENTAL
Intervention: Neridronate 100 mg given four times over 10 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 23395302

Group type: EXPERIMENTAL
Intervention: PCC Coding System (PCCCS)
Number of subjects: 30
Study: 21842171

Group type: EXPERIMENTAL
Intervention: sugammadex (2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: neostigmine (0.04 mg/kg)
Number of subjects: 0
Study: 19024312

Group type: EXPERIMENTAL
Intervention: Pulmonary static inflation with 1.0 MAC sevoflurane during CPB
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pulmonary static inflation during CPB, no sevoflurane inhaled
Number of subjects: 60
Study: 17074946

Group type: EXPERIMENTAL
Intervention: Facilitated psychiatric advance directive session
Number of subjects: 469

Group type: COMPARATOR
Intervention: Control group (written information about psychiatric advance directives and referral to resources)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 469
Study: 12673181

Group type: EXPERIMENTAL
Intervention: Standardized meal of solid food and liquid (meal group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No meal (control group)
Number of subjects: 60
Study: 10755499

Group type: EXPERIMENTAL
Intervention: E5 (murine monoclonal antibody directed against endotoxin, 2 mg/kg per day by intravenous infusion 24 hours apart)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: E5
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: E5 (in subgroup without shock)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Placebo (in subgroup without shock)
Number of subjects: 1090
Study: 8833987

Group type: EXPERIMENTAL
Intervention: Salbutamol (400 micrograms i.v.)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Broxaterol (400 micrograms i.v.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 11
Study: 1421737

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lidocaine 70 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (placebo)
Number of subjects: 22
Study: 3903786

Group type: EXPERIMENTAL
Intervention: 1.5 g triletide per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1.2 g cimetidine per day
Number of subjects: 20
Study: 31639529

Group type: EXPERIMENTAL
Intervention: FORNET (adapted Narrative Exposure Therapy)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 92
Study: 29274690

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 88

Group type: COMPARATOR
Intervention: Healthy Eating diet
Number of subjects: 88
Study: 26920597

Group type: EXPERIMENTAL
Intervention: Baseline eGFR >90
Number of subjects: 5244

Group type: EXPERIMENTAL
Intervention: Baseline eGFR 60 to 90
Number of subjects: 5244

Group type: EXPERIMENTAL
Intervention: Baseline eGFR 30 to 59
Number of subjects: 5244

Group type: EXPERIMENTAL
Intervention: Baseline eGFR <30
Number of subjects: 5244

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 5244
Study: 24515764

Group type: EXPERIMENTAL
Intervention: H&E staining
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: H&E plus p16INK4a staining
Number of subjects: 441
Study: 22140123

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 57
Study: 20090545

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 189
Study: 18058305

Group type: EXPERIMENTAL
Intervention: Betamethasone %1 cream
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Unna's Boot cream
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 90
Study: 15851794

Group type: EXPERIMENTAL
Intervention: Epoetin alfa therapy
Number of subjects: 115
Study: 12028390

Group type: EXPERIMENTAL
Intervention: Solo computer instruction (90 min of computer-guided solo instruction using 'FearFighter')
Number of subjects: 37

Group type: COMPARATOR
Intervention: Face-to-face small-group tutorial teaching (90 min)
Number of subjects: 37
Study: 9802367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micro(g) once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 200 micro(g) once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) 220 micro(g) once daily
Number of subjects: 20
Study: 7713046

Group type: EXPERIMENTAL
Intervention: F2 (2.0 g/100 ml protein formula)
Number of subjects: 16

Group type: COMPARATOR
Intervention: F1.5 (1.5 g/100 ml protein formula)
Number of subjects: 16
Study: 2554715

Group type: EXPERIMENTAL
Intervention: Lactovegetarian diet
Number of subjects: 0
Study: 27203

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30982113

Group type: EXPERIMENTAL
Intervention: Moving Forward intervention trial (randomized, community-based, 6-month weight loss study)
Number of subjects: 210
Study: 28259556

Group type: EXPERIMENTAL
Intervention: Moxidectin pour-on (Cydectin® 0.5% Pour-On, Zoetis) administered during the dry period (7–77 days before parturition) to 638 animals
Number of subjects: 1287

Group type: COMPARATOR
Intervention: Untreated group of 649 animals
Number of subjects: 1287
Study: 26012937

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin treatment in addition to calcium and vitamin D (Group I)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Calcium and vitamin D only (Group II)
Number of subjects: 25
Study: 23571802

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 7600

Group type: EXPERIMENTAL
Intervention: Percutaneous irradiation therapy
Number of subjects: 7600

Group type: EXPERIMENTAL
Intervention: Permanent seed implantation
Number of subjects: 7600

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 7600
Study: 22462232

Group type: EXPERIMENTAL
Intervention: Ganning formula (a Chinese herbal decoction)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Oral entecavir
Number of subjects: 150
Study: 19198872

Group type: COMPARATOR
Intervention: Hypohydration -0% (EU)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypohydration -1% (H1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypohydration -2% (H2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypohydration -3% (H3)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypohydration severity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluid controlling hormones (Antidiuretic hormone and aldosterone)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide
Number of subjects: 8
Study: 16432056

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (Warfarin or Aspirin)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Severe stenosis > or =70%
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Enrollment within 17 days after qualifying event
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 569
Study: 15301617

Group type: EXPERIMENTAL
Intervention: Modified visual search task with old and new objects preview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simplified displays in visual search task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outlines around distractor groups to aid segmentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiment 4 ruling out spatial disengagement problems
Number of subjects: 0
Study: 11587491

Group type: EXPERIMENTAL
Intervention: dl‐MPH‐IR after food
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: dl‐MPH‐SR after food
Number of subjects: 24

Group type: COMPARATOR
Intervention: dl‐MPH‐IR after fasting
Number of subjects: 24

Group type: COMPARATOR
Intervention: dl‐MPH‐SR after fasting
Number of subjects: 24
Study: 9045347

Group type: EXPERIMENTAL
Intervention: Carboplatin administered over 30 minutes and paclitaxel over 3 hours, every 4 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Paclitaxel before carboplatin in ovarian cancer patients
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Increasing paclitaxel doses from 100 to 250 mg/m2
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC and decrease in platelets
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combination of carboplatin and paclitaxel
Number of subjects: 83
Study: 7904761

Group type: EXPERIMENTAL
Intervention: ipsapirone (10 mg to 30 mg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg to 6 mg daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study: 3602267

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30765508

Group type: EXPERIMENTAL
Intervention: Omipalisib (0.25 mg, 1 mg, and 2 mg twice daily for 8 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30073929

Group type: EXPERIMENTAL
Intervention: PEM therapy (Serrazyme and other constituents) for 2 months
Number of subjects: 450
Study: 26873336

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined Training (CT)
Number of subjects: 81
Study: 24197970

Group type: EXPERIMENTAL
Intervention: ozonated oil‐zinc oxide
Number of subjects: 60

Group type: COMPARATOR
Intervention: zinc oxide‐eugenol
Number of subjects: 60
Study: 21601462

Group type: EXPERIMENTAL
Intervention: Extramedullary tibial instrumentation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intramedullary tibial instrumentation
Number of subjects: 56
Study: 19770635

Group type: EXPERIMENTAL
Intervention: Capecitabine (2000 mg/m/day for 14 days, once every 3 weeks) plus erlotinib (150 mg/day)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m as a 30-min infusion) plus erlotinib (150 mg/day)
Number of subjects: 281
Study: 17351084

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) motor-tracking task
Number of subjects: 24
Study: 16037756

Group type: EXPERIMENTAL
Intervention: Phytoestrogen-containing supplement (soy isoflavones and Actaea racemosa)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 11967598

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine‐chlorhexidine impregnated (SSC) catheters
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Silver, platinum and carbon incorporated (SP+C) catheters
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Minocycline and rifampin bonded (M+R) catheters
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non‐antiseptic central venous catheter segments
Number of subjects: 90
Study: 10460765

Group type: EXPERIMENTAL
Intervention: Double patch with tape
Number of subjects: 435

Group type: COMPARATOR
Intervention: No patch with tape
Number of subjects: 435
Study: 8532911

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus hormone therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 9
Study: 2092324

Group type: EXPERIMENTAL
Intervention: calcitonin (415 pmol i.v. bolus + continuous infusion during 90 min to reach an overall dose of 62.25 pmol.kg‐1 body mass)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: calcitonin
Number of subjects: 8
Study: 353458

Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg twice a day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg twice a day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Spironolactone + alpha-methyldopa (250 mg three times a day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + alpha-methyldopa (250 mg three times a day)
Number of subjects: 16
Study: 31870835

Group type: EXPERIMENTAL
Intervention: Low serum magnesium levels
Number of subjects: 3380

Group type: EXPERIMENTAL
Intervention: High calcium–magnesium ratios
Number of subjects: 3380
Study: 30509553

Group type: EXPERIMENTAL
Intervention: iCook 4-H treatment group
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study: 28439574

Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 33

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 33
Study: 26399574

Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: Bordered polyurethane dressing
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: Sutureless securement device
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Standard polyurethane dressing
Number of subjects: 1708
Study: 24166518

Group type: EXPERIMENTAL
Intervention: N/F mutations (NOTCH1 and/or FBXW7)
Number of subjects: 212

Group type: COMPARATOR
Intervention: No N/F mutations
Number of subjects: 212

Group type: COMPARATOR
Intervention: K-RAS mutations
Number of subjects: 212

Group type: COMPARATOR
Intervention: N-RAS mutations
Number of subjects: 212

Group type: COMPARATOR
Intervention: PTEN mutations/deletions
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: N/F mutations without RAS/PTEN abnormalities
Number of subjects: 212

Group type: COMPARATOR
Intervention: N/F mutations with RAS/PTEN mutations
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Oncogenetic classifier
Number of subjects: 212
Study: 20957601

Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy (LP)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Open pyloromyotomy (OP)
Number of subjects: 492
Study: 19040678

Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release 1000 mg daily after initial 500 mg for 15 days
Number of subjects: 112
Study: 17062029

Group type: EXPERIMENTAL
Intervention: Pulse itraconazole (200 mg twice daily, 1 week on, 3 weeks off, for 12 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Continuous terbinafine (250 mg once daily for 12 weeks)
Number of subjects: 63
Study: 14732756

Group type: EXPERIMENTAL
Intervention: 192-Iridium IRT
Number of subjects: 130
Study: 11564447

Group type: EXPERIMENTAL
Intervention: Delta4,16‐androstadien‐3‐one
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 1,3,5,(10),16‐estratetraen‐3‐ol
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (clove oil and propylene glycol)
Number of subjects: 65
Study: 9610580

Group type: EXPERIMENTAL
Intervention: Transurethral alprostadil therapy
Number of subjects: 452
Study: 8138933

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms s.c.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3261548

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg administered sublingually one minute before anaesthetic induction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no nifedipine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nifedipine group
Number of subjects: 30
Study: 31839571

Group type: EXPERIMENTAL
Intervention: High protein/low carbohydrate low-calorie diet (Diet HP)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Standard low-calorie diet (Diet S)
Number of subjects: 268
Study: 29496320

Group type: EXPERIMENTAL
Intervention: 3-concentration-time points limited sampling model (0.5, 2, and 8 hours)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3-concentration-time points limited sampling model (0.75, 2, and 8 hours)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3-concentration-time points limited sampling model for saroglitazar sulfoxide
Number of subjects: 50
Study: 28807988

Group type: EXPERIMENTAL
Intervention: NIV (8 cm H2O inspiratory pressure, 4 cm H2O expiratory pressure, FIO2 0.5)
Number of subjects: 271

Group type: COMPARATOR
Intervention: High-flow nasal cannula (flow 50 L/min, FIO2 0.5)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 271

Group type: COMPARATOR
Intervention: High-flow nasal cannula
Number of subjects: 271
Study: 25055809

Group type: EXPERIMENTAL
Intervention: Monetary gains
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Monetary penalties
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pre-treatment cortico-striatal connectivity
Number of subjects: 26
Study: 23123099

Group type: EXPERIMENTAL
Intervention: EMG biofeedback during exercises
Number of subjects: 25

Group type: COMPARATOR
Intervention: Exercise only (without EMG biofeedback)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 25
Study: 22006106

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy for 5 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Waiting list control for 5 weeks
Number of subjects: 83
Study: 18192493

Group type: EXPERIMENTAL
Intervention: Functional knee brace
Number of subjects: 150

Group type: COMPARATOR
Intervention: Neoprene sleeve
Number of subjects: 150
Study: 16457716

Group type: EXPERIMENTAL
Intervention: Buprenorphine patch
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 2500